Igalmi (dexmedetomidine)

Override(s)	Approval Duration
Prior Authorization	1 year
Quantity Limit	

Medications	Quantity Limit
Igalmi (dexmedetomidine) sublingual film	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Igalmi (dexmedetomidine) may be approved if the following criteria are met:

- I. Individual is 18 years of age or older; **AND**
- II. Individual has been diagnosed with schizophrenia or bipolar I or II disorder; AND
- III. Individual is using for the acute treatment of agitation under the supervision of a healthcare provider.

Igalmi (dexmedetomidine) may not be approved for the following:

- I. Individuals with hypotension, orthostatic hypotension, advanced heart block, severe ventricular dysfunction, or history of syncope; **OR**
- II. Individuals using medications that increase the QT interval (including class 1A antiarrhythmics [including quinidine, procainamide] or class III antiarrhythmics [including amiodarone, sotalol], other antipsychotic agents [such as ziprasidone, chlorpromazine, thioridazine], antibiotics [including gatifloxacin, moxifloxacin]) and cannot discontinue the medication; OR
- III. Individuals at risk for torsades de pointes or sudden death, including those with known QT prolongation, history of cardiac arrhythmias, symptomatic bradycardia, hypokalemia or hypomagnesemia.

Key References:

- 1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2022. URL: http://www.clinicalpharmacology.com. Updated periodically.
- 2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed: April 10, 2022.
- 3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
- 4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2022; Updated periodically.

Federal and state laws or requirements, contract language, and Plan utilization management programs or polices may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.